Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.

Journal of the National Cancer Institute - 11 Apr 2022

Schrijver Lieske H, Mooij Thea M, Pijpe Anouk, Sonke Gabe S, Mourits Marian J E, Andrieu Nadine, Antoniou Antonis C, Easton Douglas F, Engel Christoph, Goldgar David, John Esther M, Kast Karin, Milne Roger L, Olsson Håkan, Phillips Kelly-Anne, Terry Mary Beth, Hopper John L, van Leeuwen Flora E, Rookus Matti A

Abstract excerpt

BACKGROUND: To help BRCA1 and 2 mutation carriers make informed decisions regarding use of combined-type oral contraceptive preparation (COCP), absolute risk-benefit estimates are needed for COCP-associated cancer. METHODS: For a hypothetical cohort of 10 000 women, we calculated the increased or decreased cumulative incidence of COCP-associated (breast, ovarian, endometrial) cancer, examining 18 scenarios with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Ovarian Neoplasms

Share to Ovariectomy

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 35048954
DOI: 10.1093/jnci/djac004
PMCID: PMC9002279

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.PMID 35048954Read ↗

Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.Semantic proximity Read ↗

Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.Semantic proximity Read ↗

Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.Semantic proximity Read ↗

Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies.Semantic proximity Read ↗

Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group.Semantic proximity Read ↗

Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis.Semantic proximity Read ↗

Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.Semantic proximity Read ↗

Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review.Semantic proximity Read ↗

Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.Semantic proximity Read ↗

Clinical Inquiry: do oral contraceptives put women with a family history of breast cancer at increased risk?Semantic proximity Read ↗

Management options after prophylactic surgeries in women with BRCA mutations: a review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.